2. Search Result
Search Result
Results for "

5-lipoxygenase-activating protein

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-50714
    Quiflapon sodium
    1 Publications Verification

    MK-591 sodium

    		 FLAP Apoptosis Inflammation/Immunology
    Quiflapon sodium (MK-591 sodium) is a selective and specific 5-Lipoxygenase-activating protein (FLAP) inhibitor. Quiflapon sodium is an orally active Leukotriene biosynthesis inhibitor. Induces apoptosis.
    Quiflapon sodium
  • HY-15874
    Fiboflapon

    GSK2190915; AM-803

    		 FLAP Leukotriene Receptor Inflammation/Immunology
    Fiboflapon (GSK2190915; AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein (FLAP) inhibitor with a potency of 2.9 nM in FLAP binding, an IC50 of 76 nM for inhibition of LTB4 in human blood .
    Fiboflapon
  • HY-15874A
    Fiboflapon sodium

    GSK2190915 sodium salt; AM-803 sodium

    		 FLAP Leukotriene Receptor Inflammation/Immunology
    Fiboflapon sodium (GSK2190915; AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein (FLAP) inhibitor with a potency of 2.9 nM in FLAP binding, an IC50 of 76 nM for inhibition of LTB4 in human blood .
    Fiboflapon sodium
  • HY-14460
    AM679

    		FLAP Inflammation/Immunology
    AM679 is a potent, selective 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC50 of 2 nM in a human FLAP membrane binding assay. AM679 markedly reduces the respiratory syncytial virus-driven ocular pathology as well as the synthesis of cysteinyl leukotrienes (CysLTs) in the eye .
    AM679
  • HY-12995A
    (S)-BI 665915

    		FLAP Inflammation/Immunology
    (S)-BI 665915 is an orally active oxadiazole-containing 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC50 of 1.7 nM for FLAP binding. (S)-BI 665915 inhibits FLAP functional in human whole blood with an IC50 of 45 nM. (S)-BI 665915 demonstrates an excellent cross-species agent metabolism and pharmacokinetics (DMPK) profile and a dose-dependent inhibition of LTB4 production .
    (S)-BI 665915
  • HY-156194
    FLAP-IN-1

    		FLAP Cardiovascular Disease
    FLAP-IN-1 (Intermediate 14) is a 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC50 value of 654 nM. FLAP-IN-1 can be used in cardiovascular disease research .
    FLAP-IN-1
  • HY-118979
    L-691678

    		Leukotriene Receptor Inflammation/Immunology
    L-691678 can bind to FLAP by recognizing the amino acid residues of 5-lipoxygenase-activating protein (FLAP), thereby inhibiting leukotriene biosynthesis. L-691678 can be used in the study of leukotriene-related diseases such as allergies, asthma, and inflammation .
    L-691678
  • HY-12995
    BI 665915

    		FLAP Cardiovascular Disease Inflammation/Immunology
    BI 665915 is an orally active and potent 5-lipoxygenase-activating protein (FLAP) inhibitor. BI 665915 inhibits FLAP production that blocks LTB4 biosynthesis in mice. BI 665915 is promising for research of various inflammatory diseases, including respiratory and cardiovascular diseases .
    BI 665915
  • HY-151619
    sEH inhibitor-12

    		Epoxide Hydrolase Inflammation/Immunology
    sEH inhibitor-12 (compound 34) is a sEH inhibitor with an IC50 value of 0.7 μM. sEH inhibitor-12 inhibits the 5-lipoxygenase-activating protein (FLAP)-mediated leukotriene (LT) biosynthesis with an IC50 value of 2.9 μM. sEH inhibitor-12 can be used for the research of inflammation .
    sEH inhibitor-12
  • HY-155204
    LTB4-IN-2

    		Leukotriene Receptor FLAP Inflammation/Immunology
    LTB4-IN-2 (Comopund 6x) is a Leukotriene B4 (LTB4) inhibitor. LTB4-IN-2 inhibits Leukotriene B4 formation (IC50: 1.15 μM) by selectively targeting 5-Lipoxygenase-activating protein (FLAP). LTB4-IN-2 can be used for anti-inflammatory research .
    LTB4-IN-2
  • HY-128171
    Diflapolin
    1 Publications Verification

    		 FLAP Epoxide Hydrolase Inflammation/Immunology
    Diflapolin is a highly active dual 5-lipoxygenase-activating protein (FLAP)/soluble epoxide hydrolase (sEH) inhibitor with marked anti-inflammatory efficacy and high target selectivity. Diflapolin inhibits 5-LOX product formation in intact human monocytes and neutrophils with IC50s?of? 30 and 170?nM, respectively, and suppressed the activity of isolated sEH (IC50=20?nM) .
    Diflapolin
  • HY-10037
    Quiflapon
    1 Publications Verification

    MK-591

    		 FLAP Apoptosis Inflammation/Immunology
    Quiflapon (MK-591) is a selective and specific 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC50?of 1.6 nM in a FLAP binding assay. Quiflapon is also a potent and orally active?Leukotriene biosynthesis (LT)?inhibitor, shows IC50?values of 3.1 and 6.1 nM in intact human and elicited rat PMNLs, respectively. Quiflapon induces cell apoptosis .
    Quiflapon
  • HY-122908
    Atuliflapon

    AZD5718

    		 FLAP Cardiovascular Disease
    Atuliflapon (AZD5718) is an orally active inhibitor of FLAP (5‑Lipoxygenase activating protein), with an IC50 of 2 nM. Atuliflapon is used in the study for coronary artery disease .
    Atuliflapon
  • HY-14165
    Veliflapon

    BAY X 1005; DG-031

    		 FLAP Leukotriene Receptor Cardiovascular Disease Inflammation/Immunology
    Veliflapon (BAY X 1005; DG-031) is an orally active and selective 5-lipoxygenase activating protein (FLAP) inhibitor . Veliflapon inhibits the synthesis of the leukotrienes B4 and C4 .
    Veliflapon
  • HY-14165A
    (S)-Veliflapon

    (S)-BAY X 1005; (S)-DG-031

    		 Leukotriene Receptor FLAP Inflammation/Immunology
    (S)-Veliflapon ((S)-BAY X 1005) is an orally active inhibitor of leukotriene biosynthesis and 5-lipoxygenase activating protein (FLAP). (S)-Veliflapon inhibits the formation of leukotriene B4 (LTB4) in rat, mouse and human leukocytes with IC50 values of 0.026 µM, 0.039 µM and 0.22 µM respectively. (S)-Veliflapon showes enantioselectivity in human whole blood .
    (S)-Veliflapon
  • HY-155407
    ALR-6

    		FLAP Inflammation/Immunology
    ALR-6 is an antagonist of the 5-lipoxygenase (5-LOX) activating protein FLAP and has anti-inflammatory activity. ALR-6 potently inhibits 5-LOX product formation (>80%) in pro-inflammatory M1-MDM and has no significant effect on direct inhibition of 5-LOX .
    ALR-6
  • HY-155408
    ALR-27

    		FLAP Inflammation/Immunology
    ALR-27 is an antagonist of the 5-lipoxygenase (5-LOX) activating protein FLAP and has anti-inflammatory activity. ALR-27 potently inhibits 5-LOX product formation (>80%) in pro-inflammatory M1-MDM, with no significant direct inhibition of 5-LOX. ALR-27 not only reduces prostaglandin and leukotriene (LT) production in neutrophils but also increases the production of specialized prolytic mediators in specific human macrophage phenotypes .
    ALR-27
  • HY-155409
    ALR-38

    		Lipoxygenase Inflammation/Immunology
    ALR-38 is a 5-lipoxygenase (5-LOX) inhibitor (IC50: 1.1 μM) with anti-inflammatory activity. ALR-38 effectively reduces ROS levels in neutrophils .
    ALR-38

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: